拜玛林制药 BMRN 深 沪
等待开盘 06-26 09:30:00 美东时间
57.34
+0.010
+0.02%
华盛通- 最 高57.9499
- 今 开57.46
- 成交量 110.50万股
- 最 低 54.96
- 昨 收 57.33
- 总市值 1060.79万
- 52周最高 66.275
- 市盈率 静 --
- 换手率 597.27%
- 52周最低 49.2592
- 委 比 -89.66%
- 总股本 0.00亿
- 历史最高 151.75
- 量 比 0.57
- 振 幅 5.22%
- 历史最低 1.10
- 每 手 1
- 风险率 2.78%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BioMarin Reveals Dwarfism Study Data, Stock Soars
BioMarin stock climbed after Phase 3 VOXZOGO data showed significant growth improvements in children with hypochondroplasia.
05-22 02:11
Earnings Scheduled For May 4, 2026
Companies Reporting Before The Bell • Pulse Biosciences (NASDAQ:PLSE) is likely...
05-04 19:11
BridgeBio's Rare-Disease Pipeline Sparks Growth Buzz
BridgeBio's rare-disease pipeline draws investor attention as new therapies near regulatory filings and potential commercial launches.
03-11 02:49
BioMarin Strengthens PKU Portfolio With FDA Approval For Younger Patients
The FDA approved BioMarin's supplemental BLA for Palynziq, a treatment for PKU in adolescents 12 and older.
03-02 19:10
Earnings Scheduled For February 23, 2026
Companies Reporting Before The Bell • Domino's Pizza (NASDAQ:DPZ) is likely to ...
02-23 19:11
Reported Earlier: BioMarin Launches $2B Term Loan B Financing To Fund Pending Amicus Therapeutics Acquisition
BioMarin also announced that, in connection with the pending acquisition (the "Acquisition") of Amicus Therapeutics, Inc. ("Amicus"), it launched the syndication of a new $2 billion senior secured term loan "B" facility
01-26 21:49
BioMarin Pharmaceutical Plans To Offer $850M Senior Notes Due 2034 Offering
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ("BioMarin") announced today that it intends to offer, subject to market and other conditions, $850 million of senior unsecured notes due 2034 (the "Notes").
01-26 20:47
Nasdaq Surges Over 1%; Lamb Weston Shares Decline Following Q2 Results
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gai...
2025-12-20 01:16
BioMarin Boosts Rare Disease Portfolio With Amicus Buyout, Stocks Rally
BioMarin acquires Amicus for $4.8B, expanding its rare disease portfolio with Fabry and Pompe therapies, in a deal expected to close Q2 2026.
2025-12-20 00:07
GSK Deal Is Key Validation For CAMP4's Drug Discovery Platform: Analyst
CAMP4 signs ASO collaboration with GSK, securing $17.5 million upfront as analysts reaffirm Outperform and highlight 2026 clinical milestones.
2025-12-19 23:36
